Top

Published in:

01-05-2021 | COVID-19 | Research Letter

Markers of coagulation dysfunction and inflammation in diabetic and non-diabetic COVID-19

Authors: Seshadri Reddy Varikasuvu, Saurabh Varshney, Naveen Dutt

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2021

Abstract

Coagulation dysfunction and inflammatory status were compared between diabetic and non-diabetic COVID-19 patients. The standardized mean difference (SMD) and its 95% confidence interval (CI) was computed for the difference of inflammatory and hypercoagulability markers. The levels of serum ferritin (standardized mean difference-SMD: 0.47, CI 0.17–0.77, p = 0.002), C-reactive protein (SMD = 0.53, CI 0.20–0.86, p = 0.002), interleukin-6 (SMD = 0.31, CI 0.09–0.52, p = 0.005), fibrinogen (SMD = 0.31, CI 0.09–0.54, p = 0.007) and D-dimers (SMD = 0.54, CI 0.16–0.91, p = 0.005) were significantly higher in diabetic COVID-19 cases as compared to non-diabetic COVID-19 patients, suggesting more susceptibility of diabetic COVID-19 patients to coagulation dysfunction and inflammatory storm.

Cucinotta D, Vanelli M (2020) WHO declares COVID-19 a pandemic. Acta Biomed 91:157–160PubMedPubMedCentral

Li J, Wang X, Chen J et al (2020) COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab. https://doi.org/10.1111/dom.14057CrossRefPubMedPubMedCentral

Guo W, Li M, Dong Y et al (2020) Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. https://doi.org/10.1002/dmrr.3319CrossRefPubMedPubMedCentral

Yan Y, Yang Y, Wang F et al (2020) Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care 8:e001343. https://doi.org/10.1136/bmjdrc-2020-001343CrossRefPubMedPubMedCentral

Zhang Y, Li H, Zhang J et al (2020) The clinical characteristics and outcomes of diabetes mellitus and secondary hyperglycaemia patients with coronavirus disease 2019: a single-center, retrospective, observational study in Wuhan. Diabetes Obes Metab 22:1443–1454. https://doi.org/10.1111/dom.14086CrossRefPubMed

Spiezia L, Boscolo A, Poletto F et al (2020) COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost 120:998–1000. https://doi.org/10.1055/s-0040-1710018CrossRefPubMedPubMedCentral

Li Y, Zhao K, Wei H et al (2020) Dynamic relationship between D-dimer and COVID-19 severity. Br J Haematol 190:e24–e27. https://doi.org/10.1111/bjh.16811CrossRefPubMed

Connors JM, Levy JH (2020) COVID-19 and its implications for thrombosis and anticoagulation. Blood 135:2033–2040. https://doi.org/10.1182/blood.2020006000CrossRefPubMedPubMedCentral

Jagannathan-Bogdan M, McDonnell ME, Shin H et al (2011) Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J Immunol 186:1162–1172CrossRef

10.

Yang JK, Feng Y, Yuan MY et al (2006) Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Med 23:623–628CrossRef

11.

Tanaka T, Narazaki M, Kishimoto T (2016) Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 8:959–970CrossRef

12.

Sardu C, D’Onofrio N, Balestrieri ML et al (2020) Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care 43:1408–1415. https://doi.org/10.2337/dc20-0723CrossRefPubMedPubMedCentral

13.

Di Micco P, Russo V, Carannante N et al (2020) Clotting factors in COVID-19: epidemiological association and prognostic values in different clinical presentations in an Italian Cohort. J Clin Med 9:1371. https://doi.org/10.3390/jcm9051371CrossRefPubMedCentral

14.

Han H, Yang L, Liu R et al (2020) Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 58:1116–1120. https://doi.org/10.1515/cclm-2020-0188CrossRefPubMed

Title: Markers of coagulation dysfunction and inflammation in diabetic and non-diabetic COVID-19
Authors: Seshadri Reddy Varikasuvu
Saurabh Varshney
Naveen Dutt
Publication date: 01-05-2021
Publisher: Springer US
Keyword: COVID-19
Published in: Journal of Thrombosis and Thrombolysis / Issue 4/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-020-02270-w

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Markers of coagulation dysfunction and inflammation in diabetic and non-diabetic COVID-19

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Incidence of venous thromboembolism and bleeding after pulmonary lobectomy: evaluating the timing for thromboprophylaxis

Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2

Thromboelastography findings in critically ill COVID-19 patients

Significant reductions in apoptosis-related proteins (HSPA6, HSPA8, ITGB3, YWHAH, and PRDX6) are involved in immune thrombocytopenia

Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19

Vascular-specific epicardial adipose tissue in predicting functional myocardial ischemia for patients with stable chest pain

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page